Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nalin Srivastava

Cardiovascular Disease Spartanburg, SC Medical Doctor

NPI 1023065828 CMS profile 272906

1083 Boiling Springs Rd, Spartanburg, SC 29303

Open in the dashboard

General payments

$15,334

462 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$29,915 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Nalin Srivastava of Spartanburg, SC is reported in the CMS Open Payments database as having received $15,334 across 462 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $29,915 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,912 90
2024 General $3,115 91
2023 General $1,559 86
2022 General $1,449 82
2021 General $916 51
2020 General $1,022 23
2019 General $1,360 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nalin Srivastava
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Nalin Srivastava were reported at $5,912. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Nalin Srivastava Cardiovascular Disease median Middle half National median
2019 $1,360 $450 $127–$1,392 $163
2020 $1,022 $242 $77–$751 $114
2021 $916 $335 $101–$1,037 $132
2022 $1,449 $395 $121–$1,211 $149
2023 $1,559 $443 $136–$1,283 $160
2024 $3,115 $450 $136–$1,323 $164
2025 $5,912 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $3,101 27 payments
  2. Medtronic, Inc. $3,100 42 payments
  3. Abbott Laboratories $2,649 87 payments
  4. Abiomed $856 20 payments
  5. Boston Scientific Corporation $826 43 payments
  6. Biotronik Inc. $688 12 payments
  7. Novartis Pharmaceuticals Corporation $617 34 payments
  8. Inari Medical, Inc. $542 27 payments
  9. E.R. Squibb & Sons, L.L.C. $298 16 payments
  10. Stryker Corporation $288 20 payments
  11. Other $2,368 134 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,634 431 payments
  2. Travel and Lodging $5,407 20 payments
  3. Education $293 11 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $2,870 30 payments
  2. SAPIEN 3 Ultra RESILIA $1,556 17 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,116 3 payments
  4. Impella $798 18 payments
  5. FLOWTRIEVER CATHETER, S $708 28 payments
  6. LEQVIO $377 19 payments
  7. CT THROMBECTOMY SYSTEM KIT $377 26 payments
  8. OPTIS $335 21 payments
  9. WATCHMAN $291 11 payments
  10. SYNERGY ABLATION SYSTEM $239 12 payments
  11. Other $5,290 305 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,979

Median for Interventional Cardiology: 2,236

Drug cost

$506,802

Median for Interventional Cardiology: $380,412

Branded share of claims

31.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 284 $264,727
Entresto Sacubitril/Valsartan Brand 78 $72,701
Repatha Sureclick Evolocumab Brand 45 $53,034
Xarelto Rivaroxaban Brand 64 $46,324
Praluent Pen Alirocumab Brand 15 $19,588
Brilinta Ticagrelor Brand 12 $8,409
Ranolazine Er Ranolazine Brand 64 $7,703
Atorvastatin Calcium Generic 234 $2,575
Rosuvastatin Calcium Generic 128 $2,211
Metoprolol Succinate Generic 133 $2,206

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$309,718

Of which drugs: $1,356

Medicare patients

1,483

Average age 76

Services billed

4,571

706 women, 777 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 50%
Chronic kidney disease 43%
Atrial fibrillation 41%
Heart failure 40%
Diabetes 38%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 66 252 $1,356

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $163
$163 — —
VYNDAQEL
  • PFIZER INC. $60
$60 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $59
$59 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $56
$56 284 —
Repatha
  • Amgen Inc. $20
$20 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

462 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record